Zealand Pharma A/S
CSE:ZEAL

Watchlist Manager
Zealand Pharma A/S Logo
Zealand Pharma A/S
CSE:ZEAL
Watchlist
Price: 476.4 DKK 2.23% Market Closed
Market Cap: 33.8B DKK

EV/EBIT
Enterprise Value to EBIT

-18.2
Current
-17.7
Median
4.5
Industry
Lower than median
Lower than industry value

Enterprise Value to EBIT (EV/EBIT) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s earnings before interest and taxes (EBIT). Considered one of the most frequently used multiples for comparisons among companies, the EV/EBIT multiple relies on operating income as the core driver of valuation.

EV/EBIT
-18.2
=
Enterprise Value
25.5B DKK
/
EBIT
-1.4B DKK
EBIT Growth EV/EBIT to Growth
DK
Zealand Pharma A/S
CSE:ZEAL
Average EV/EBIT: 20
Negative Multiple: -18.2
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -198 498.2 N/A N/A
US
Abbvie Inc
NYSE:ABBV
22.7
29%
0.8
US
Amgen Inc
NASDAQ:AMGN
23.4
32%
0.7
US
Gilead Sciences Inc
NASDAQ:GILD
14.1
11%
1.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
26
17%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -547.7 N/A N/A
AU
CSL Ltd
ASX:CSL
21.4
14%
1.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
12.2
11%
1.1
US
S
Seagen Inc
F:SGT
Negative Multiple: -58.1 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -329.4 N/A N/A

EV/EBIT Forward Multiples

Forward EV/EBIT multiple is a version of the EV/EBIT ratio that uses forecasted EBIT for the EV/EBIT calculation. 1-Year, 2-Years, and 3-Years forwards use EBIT forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBIT
4.3
2-Years Forward
EV/EBIT
35.9
3-Years Forward
EV/EBIT
-171.9